Skip to nav Skip to content
Richard  Kim

Richard Kim, MD

4.8 (120)

Specialty: Medical Oncology

Program: Gastrointestinal Oncology

Language(s): English

  • Overview

    Cancer Focus:
    Anal Cancer, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Stomach (Gastric) Cancer

    Dr. Richard Kim is a Service Chief of Medical Gastrointestinal Oncology and Senior Member in the Gastrointestinal Oncology Department at Moffitt Cancer Center. He is a Professor of Oncology at the University of South Florida College of Medicine. Dr. Kim received his medical degree from the University of Miami School of Medicine and completed a residency in internal medicine at the University of Illinois at Chicago. He pursued a postdoctoral fellowship in hematology and medical oncology at Yale University Comprehensive Cancer Center in New Haven, CT. Before coming to Moffitt in 2010, Dr. Kim was an associate physician in gastrointestinal malignancies at the Cleveland Clinic Taussig Cancer Center and a clinical assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, OH. Dr. Kim was named 2008 Teacher of the Year at the Cleveland Clinic and selected for the 2008 Southwest Oncology Group Young Investigator Program and SWOG’s Intergroup Colon Task Force for junior faculty. Dr. Kim’s clinical and research interests focus on gastrointestinal tumors, in particular hepatobiliary and colon cancer. He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I, II , III trials using immunotherapy and novel targeted agents. Dr. Kim has published in many peer reviewed journals including Lancet Oncology, British Journal of Cancer, JAMA Oncology, Clinical Cancer of Research, Cancer and Journal of Clinical Oncology along with many book chapters. He has been an ad hoc editorial reviewer for many professional journals, including Journal of Clinical oncology, Annals of Oncology, Cancer and Lancet Oncology. Dr Kim has spoken at over 50 national and international events, most recently ASCO Direct Highlights, the annual meeting of the Florida Academic Cancer Center Alliance, and the Spring Managed Care Forum in Orlando, FL.   

    Education & Training

    Residency:

    • University of Illinois - Internal Medicine

    Medical School:

    • University of Miami School of Medicine - MD
  • Participating Trials

    Clinical Trial 21923
    A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
    Condition: Gastrointestinal Tumor
    Intervention: Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab (); Pembrolizumab (Keytruda); TTI-101 ()
    Status: Open

    Clinical Trial 22437
    A Phase 2a, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating LSTA1 when Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors
    Condition: Gastrointestinal Tumor
    Intervention: 5-fluorouracil (); AMP-514 (Durvalumab); Durvalumab (); Gemzar (gemcitabine); LSTA1 (); MEDI4736 (Durvalumab); Oxaliplatin (); Placebo (); Taxotere (docetaxel); cisplatin (); docetaxel (); eloxatin (Oxaliplatin); gemcitabine (); leucovorin ()
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Biachi de Castria T, Kim RD. Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights. Pragmat Obs Res. 2024 Jun.15:79-87. Pubmedid: 38881691. Pmcid: PMC11178097.
    • Chen EX, Kavan P, Tehfe M, Kortmansky JS, Sawyer MB, Chiorean EG, Lieu CH, Polite B, Wong L, Fakih M, Spencer K, Chaves J, Li C, Leconte P, Adelberg D, Kim R. Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer. 2024 Jun.23(2):183-193. Pubmedid: 38653648.
    • Kim R, Tehfe M, Kavan P, Chaves J, Kortmansky JS, Chen EX, Lieu CH, Wong L, Fakih M, Spencer K, Zhao Q, Predoiu R, Li C, Leconte P, Adelberg D, Chiorean EG. Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. Clin Colorectal Cancer. 2024 Jun.23(2):118-127.e6. Pubmedid: 38762348.
    • Kim DW, Kim YC, Kovari BP, Martinez M, Miao R, Yu J, Mehta R, Strosberg J, Imanirad I, Kim RD. Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer. Cancers (Basel). 2024 Jan.16(3). Pubmedid: 38339307. Pmcid: PMC10854756.
    • Yu J, Avriett TA, Ray CM, Kim RD. Circulating tumor DNA analysis guiding adjuvant treatment in resected stage III cholangiocarcinoma: a case report. J Gastrointest Oncol. 2024 Feb.15(1):485-490. Pubmedid: 38482231. Pmcid: PMC10932665.
    • Yu J, Kim RD. Progress in the treatment of anal cancer: an overview of the latest investigational drugs. Expert Opin Inv Drug. 2024 Feb.33(2):145-157. Pubmedid: 38275174.
    • Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, Kono Y, Shah DP, Nguyen MH, Liu G, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology. 2024 Feb. Pubmedid: 38381705.
    • Biachi de Castria T, Miao R, Kim RD. Fruquintinib in Patients with Previously Treated Metastatic Colorectal Cancer. touchREVIEWS in Oncology & Haematology. 2024 Apr.20(1).
    • Kis B, Shridhar R, Mhaskar R, Gyano M, Frakes JM, El-Haddad G, Choi J, Kim RD, Hoffe SE. Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study. J Vasc Interv Radiol. 2023 Sep.34(9):1547-1555. Pubmedid: 37210030.
    • Meng L, Thapa R, Delgado MG, Gomez MF, Ji R, Knepper TC, Hubbard JM, Wang X, Permuth JB, Kim RD, Laber DA, Xie H. Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer. JAMA Netw Open. 2023 Jun.6(6):e2320035. Pubmedid: 37358854. Pmcid: PMC10293914.
    • Yu J, Park R, Kim R. Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights. J Hepatocell Carcinoma. 2023 Jul.10:1105-1127. Pubmedid: 37483311. Pmcid: PMC10362916.
    • Abou-Alfa GK, Wang X, Parrinello CM, Gossai A, Kim R, Magee K, Miksad RA. Association between posttreatment α-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma. Cancer. 2023 Jul.129(13):2064-2074. Pubmedid: 36942492.
    • Liu J, Wang X, Sahin IH, Imanirad I, Felder SI, Kim RD, Xie H. Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer. Am J Clin Oncol. 2023 Feb.46(2):50-57. Pubmedid: 36606664.
    • Stokes SM, Haider M, Vadaparampil ST, Levitt C, Hardy O, Kim R, Castillo DL, Denbo J, Fleming JB, Anaya DA. Patient's informational needs and outreach preferences: A cross-sectional survey study in patients with hepatobiliary malignancies. PEC Innov. 2023 Dec.4:100248. Pubmedid: 38292078. Pmcid: PMC10825679.
    • Kim R, Leal AD, Parikh A, Ryan DP, Wang S, Bahamon B, Gupta N, Moss A, Pye J, Miao H, Inguilizian H, Cleary JM. Correction to: A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer Chemother Pharmacol. 2023 Apr.91(4):301. Pubmedid: 36967405. Pmcid: PMC10068635.
    • Kim R, Leal AD, Parikh A, Ryan DP, Wang S, Bahamon B, Gupta N, Moss A, Pye J, Miao H, Inguilizian H, Cleary JM. A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer Chemother Pharmacol. 2023 Apr.91(4):291-300. Pubmedid: 36738333. Pmcid: PMC10068631.
    • Kumar P, Mhaskar R, Kim R, Anaya D, Frakes J, Hoffe S, Choi J, Kis B. Unresectable Intrahepatic Cholangiocarcinoma Treated with Radiation Segmentectomy/Lobectomy Using Yttrium 90-labeled Glass Microspheres. J Clin Exp Hepatol. 2022 Sep.12(5):1259-1263. Pubmedid: 36157145. Pmcid: PMC9499841.
    • Kim DW, Kim YC, Kovari BP, Chung V, Alese OB, El-Rayes BF, Li D, Park W, Kim RD. Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer. Eur J Cancer. 2022 Nov.176:171-180. Pubmedid: 36252287.
    • Crowder SL, Hoogland AI, Small BJ, Carpenter KM, Fischer SM, Li D, Kinney AY, Welniak TL, Brownstein N, Reich RR, Hembree T, Extermann M, Kim R, Afiat TP, Berry DL, Turner K, Jim HSL. Associations among frailty and quality of life in older patients with cancer treated with chemotherapy. Geriatr Oncol. 2022 Nov.13(8):1149-1155. Pubmedid: 36008271. Pmcid: PMC9871794.
    • Tan E, Whiting J, Xie H, Imanirad I, Carballido E, Felder S, Frakes J, Mo Q, Walko C, Permuth JB, Sommerer K, Kim R, Anaya DA, Fleming JB, Sahin IH. BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer. Oncologist. 2022 Mar.27(3):191-197. Pubmedid: 35274712. Pmcid: PMC8914499.
    • Sinnamon AJ, Wood AC, Satyadi MA, Levitt CV, Hardy O, Haider M, Kim RD, Anaya DA, Denbo JW. Anatomic patterns of recurrence in biliary tract cancers: does primary tumor site matter?. J Gastrointest Oncol. 2022 Jun.13(3):1413-1422. Pubmedid: 35837169. Pmcid: PMC9274032.
    • Kim RD, Kovari BP, Martinez M, Xie H, Sahin IH, Mehta R, Strosberg J, Imanirad I, Ghayouri M, Kim YC, Kim DW. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022 Jul.169:93-102. Pubmedid: 35526308.
    • Crowder SL, Hoogland AI, Welniak TL, LaFranchise EA, Carpenter KM, Li D, Rotroff DM, Mariam A, Pierce CM, Fischer SM, Kinney AY, Dong-Binh Tran T, Rastegari F, Berry DL, Extermann M, Kim RD, Tometich DB, Figueiredo JC, Muzaffar J, Bari S, Turner K, Weinstock GM, Jim HSL. Metagenomics and chemotherapy-induced nausea: A roadmap for future research. Cancer. 2022 Feb.128(3):461-470. Pubmedid: 34643945. Pmcid: PMC8776572.
    • Crowder SL, Welniak TL, Hoogland AI, Small BJ, Rodriguez Y, Carpenter KM, Fischer SM, Li D, Kinney AY, Rotroff D, Mariam A, Brownstein N, Reich RR, Hembree T, Playdon MC, Arthur AE, Vieytes CA, Li Z, Extermann M, Kim R, Berry DL, Jim HSL. Diet quality indices and changes in cognition during chemotherapy. Support Care Cancer. 2022 Dec.31(1):75. Pubmedid: 36544032. Pmcid: PMC10127432.
    • Kalyan A, Khosla H, Kim RD. Immunotherapy in Biliary Tract Cancers: Where Are We?. Curr Oncol Rep. 2022 Dec.24(12):1821-1828. Pubmedid: 36192517.
    • Mehta R, Frakes J, Kim J, Nixon A, Liu Y, Howard L, Martinez Jimenez ME, Carballido E, Imanirad I, Sanchez J, Dessureault S, Xie H, Felder S, Sahin I, Hoffe S, Malafa M, Kim R. Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. Oncologist. 2022 Aug.27(8):621-e617. Pubmedid: 35325225. Pmcid: PMC9355805.
    • Karan C, Tan E, Sarfraz H, Knepper TC, Walko CM, Felder S, Kim R, Sahin IH. Human Epidermal Growth Factor Receptor 2-Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues. JCO Oncol Pract. 2022 Aug.18(8):545-554. Pubmedid: 35613416.
    • Xie H, Alem Glison DM, Kim RD. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential. Expert Opin Inv Drug. 2022 Apr.31(4):393-400. Pubmedid: 34913780.
    • Ehab J, Powers B, Kim R, Haider M, Utuama O, Chin A, Denbo J, Kis B, Frakes J, Jeong D, Lauwers G, Vadaparampil S, Fleming JB, Anaya DA. ASO Visual Abstract: Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients with Liver Malignancies. Ann Surg Oncol. 2022 Apr.29(4):2381-2382. Pubmedid: 34716839.
    • Tan E, Whiting J, Knepper T, Xie H, Imanirad I, Carballido E, Felder S, Frakes J, Mo Q, Permuth JB, Somerer K, Kim R, Anaya DA, Fleming JB, Walko C, Sahin IH. Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers. Am J Clin Oncol. 2022 Apr.45(4):137-141. Pubmedid: 35320814.
    • Ehab J, Powers B, Kim R, Haider M, Utuama O, Chin A, Denbo J, Kis B, Frakes J, Jeong D, Lauwers G, Vadaparampil S, Fleming JB, Anaya DA. Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients With Liver Malignancies. Ann Surg Oncol. 2022 Apr.29(4):2371-2380. Pubmedid: 34671878.
    • Sahin IH, Ciombor KK, Diaz LA, Yu J, Kim R. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues. Am Soc Clin Oncol Educ Book. 2022 Apr.42:1-12. Pubmedid: 35658496.
    • Yu J, Mahipal A, Kim R. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. Onco Targets Ther. 2021 Oct.14:5145-5160. Pubmedid: 34720591. Pmcid: PMC8550543.
    • Felder SI, Feuerlein S, Parsee A, Imanirad I, Sanchez J, Dessureault S, Kim R, Hoffe S, Frakes J, Costello J. Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples. Abdom Radiol (NY). 2021 May.46(5):1783-1804. Pubmedid: 33111189.
    • Kim DW, Tan E, Zhou JM, Schell MJ, Martinez M, Yu J, Carballido E, Mehta R, Strosberg J, Imanirad I, Kim RD. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. Brit J Cancer. 2021 May.124(11):1803-1808. Pubmedid: 33828254. Pmcid: PMC8144213.
    • Xie H, Kim RD. The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer. Ann Surg Oncol. 2021 Mar.28(3):1845-1858. Pubmedid: 32776184.
    • Yang X, Yin H, Kim RD, Fleming JB, Xie H. Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective. Target Oncol. 2021 Jan.16(1):1-12. Pubmedid: 33369705.
    • Anaya DA, Dogra P, Wang Z, Haider M, Ehab J, Jeong DK, Ghayouri M, Lauwers GY, Thomas K, Kim R, Butner JD, Nizzero S, Ramírez JR, Plodinec M, Sidman RL, Cavenee WK, Pasqualini R, Arap W, Fleming JB, Cristini V. A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases. Cancers (Basel). 2021 Jan.13(3). Pubmedid: 33503971. Pmcid: PMC7866038.
    • Yuan Z, Frazer M, Rishi A, Latifi K, Tomaszewski MR, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Zhang GG, Frakes JM. Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy. Rep Pract Oncol Radiother. 2021 Feb.26(1):29-34. Pubmedid: 33948299. Pmcid: PMC8086711.
    • Denbo JW, Kim R, Anaya DA. ASO Author Reflections: Evolving Treatment Paradigms for High-Risk Intrahepatic Cholangiocarcinoma: What Does The Future Hold?. Ann Surg Oncol. 2021 Dec.28(Suppl 3):854-855. Pubmedid: 33891197.
    • Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R. Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. J Comp Eff Res. 2021 Apr.10(5):343-352. Pubmedid: 33442996.
    • Mehta R, Wood AC, Yu J, Kim R. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. Expert Opin Inv Drug. 2021 Apr.30(4):451-461. Pubmedid: 33660569.
    • Utuama O, Permuth JB, Dagne G, Sanchez-Anguiano A, Alman A, Kumar A, Denbo J, Kim R, Fleming JB, Anaya DA. Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Ann Surg Oncol. 2021 Apr.28(4):1939-1949. Pubmedid: 33415559.
    • Tan ES, Cao B, Kim J, Al-Toubah TE, Mehta R, Centeno BA, Kim RD. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers. Cancer. 2021 Apr.127(8):1293-1300. Pubmedid: 33289918.
    • Sahin IH, Tan E, Kim R. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma. Expert Opin Inv Drug. 2021 Apr.30(4):333-341. Pubmedid: 33378249.
    • Yuan Z, Frazer M, Ahmed KA, Naqvi SMH, Schell MJ, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Torres-Roca JF, Hoffe SE, Frakes JM. Modeling precision genomic-based radiation dose response in rectal cancer. Future Oncol. 2020 Oct.16(30):2411-2420. Pubmedid: 32686956.
    • Mahipal A, Tella SH, Kommalapati A, Yu J, Kim R. Prevention and treatment of FGFR inhibitor-associated toxicities. Crit Rev Oncol Hematol. 2020 Nov.155:103091. Pubmedid: 32961472.
    • Frazer ML, Yang G, Felder S, McDonald J, Sanchez J, Dessureault S, Imanirad I, Carballido E, Kim RD, Hoffe SE, Frakes JM. Determining Optimal Follow-up for Patients With Anal Cancer Following Chemoradiation. Am J Clin Oncol. 2020 May.43(5):319-324. Pubmedid: 32028341.
    • Kim RD, McDonough S, El-Khoueiry AB, Bekaii-Saab TS, Stein SM, Sahai V, Keogh GP, Kim EJ, Baron AD, Siegel AB, Barzi A, Guthrie KA, Javle M, Hochster H. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. Eur J Cancer. 2020 May.130:219-227. Pubmedid: 32234665. Pmcid: PMC7539324.
    • Yuan Z, Frazer M, Zhang GG, Latifi K, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Frakes JM. CT-based radiomic features to predict pathological response in rectal cancer: A retrospective cohort study. J Med Imaging Radiat Oncol. 2020 Jun.64(3):444-449. Pubmedid: 32386109.
    • Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, Schell MJ, Zhou JM, Mahipal A, Kim BH, Kim DW. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol. 2020 Jun.6(6):888-894. Pubmedid: 32352498. Pmcid: PMC7193528.
    • Kim RD, Azad NS, Morse MA, Poplin E, Mahipal A, Tan B, Mavroukakis SA, Fantini M, Tsang KY, Zaki A, Torrealba J, Arlen PM, Beg MS. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul.26(14):3557-3564. Pubmedid: 32303539.
    • Mehta R, Kommalapati A, Kim RD. The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer. Cancer Manag Res. 2020 Jan.12:51-57. Pubmedid: 32021422. Pmcid: PMC6954857.
    • Challa S, Husain K, Kim R, Coppola D, Batra SK, Cheng JQ, Malafa MP. Targeting the IκB Kinase Enhancer and Its Feedback Circuit in Pancreatic Cancer. Transl Oncol. 2020 Feb.13(2):481-489. Pubmedid: 32004866. Pmcid: PMC6994835.
    • Xie H, Kim RD. ASO Author Reflections: Clinical Utility of Circulating Tumor DNA Analysis in Colorectal Cancer: Current Status. Ann Surg Oncol. 2020 Dec.27(Suppl 3):890. Pubmedid: 32812106.
    • Kim R, Tan E, Wang E, Mahipal A, Chen DT, Cao B, Masawi F, Machado C, Yu J, Kim DW. A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. Oncologist. 2020 Dec.25(12):e1893-e1899. Pubmedid: 32776632. Pmcid: PMC8186409.
    • Kim DW, Schell MJ, Kim RD. Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer-Reply. JAMA Oncol. 2020 Dec.6(12):1981-1982. Pubmedid: 33090188.
    • Kim RD, Sanoff HK, Poklepovic AS, Soares H, Kim J, Lyu J, Liu Y, Nixon AB, Kim DW. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer. 2020 Aug.126(15):3464-3470. Pubmedid: 32453456. Pmcid: PMC7787270.
    • Kis B, Mills M, Smith J, Choi J, Sagatys E, Komrokji R, Strosberg J, Kim RD. Partial Splenic Artery Embolization in 35 Cancer Patients: Results of a Single Institution Retrospective Study. J Vasc Interv Radiol. 2020 Apr.31(4):584-591. Pubmedid: 31471193.
    • Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Br J Clin Pharmacol. 2019 Nov.85(11):2499-2511. Pubmedid: 31271459. Pmcid: PMC6848909.
    • Bekaii-Saab T, Kim R, Kim TW, O'Connor JM, Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K, Yoshino T, Prager GW. Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. Clin Colorectal Cancer. 2019 Mar.18(1):e117-e129. Pubmedid: 30598357.
    • Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs. 2019 Jun.37(3):473-481. Pubmedid: 30298303. Pmcid: PMC7771270.
    • Mahipal A, Tella SH, Kommalapati A, Anaya D, Kim R. FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma. Cancer Treat Rev. 2019 Jun.78:1-7. Pubmedid: 31255945.
    • Mahipal A, Tella SH, Kommalapati A, Lim A, Kim R. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?. Cancers (Basel). 2019 Jul.11(8). Pubmedid: 31366113. Pmcid: PMC6721326.
    • Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, Finn RS. The Role of Angiogenesis in Hepatocellular Carcinoma. Clin Cancer Res. 2019 Feb.25(3):912-920. Pubmedid: 30274981.
    • Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discov. 2019 Dec.9(12):1696-1707. Pubmedid: 31575541.
    • Hatlen MA, Schmidt-Kittler O, Sherwin CA, Rozsahegyi E, Rubin N, Sheets MP, Kim JL, Miduturu C, Bifulco N, Brooijmans N, Shi H, Guzi T, Boral A, Lengauer C, Dorsch M, Kim RD, Kang YK, Wolf BB, Hoeflich KP. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. Cancer Discov. 2019 Dec.9(12):1686-1695. Pubmedid: 31575540.
    • Mahipal A, Kommalapati A, Tella SH, Lim A, Kim R. Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opin Inv Drug. 2018 Sep.27(9):709-720. Pubmedid: 30124336.
    • Kim R, Coppola D, Wang E, Chang YD, Kim Y, Anaya D, Kim DW. Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma. Oncotarget. 2018 May.9(34):23366-23372. Pubmedid: 29805739. Pmcid: PMC5955104.
    • Sajjad M, Batra S, Hoffe S, Kim R, Springett G, Mahipal A. Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis. Am J Clin Oncol. 2018 Mar.41(3):236-241. Pubmedid: 26796313.
    • Frakes JM, Abuodeh YA, Naghavi AO, Echevarria MI, Shridhar R, Friedman M, Kim R, El-Haddad G, Kis B, Biebel B, Sweeney J, Choi J, Anaya D, Giuliano AR, Hoffe SE. Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization. J Gastrointest Oncol. 2018 Jun.9(3):546-552. Pubmedid: 29998020. Pmcid: PMC6006034.
    • Chang YD, Smith J, Portman D, Kim R, Oberoi-Jassal R, Rajasekhara S, Davis M. Single Institute Experience With Methylphenidate and American Ginseng in Cancer-Related Fatigue. Am J Hosp Palliat Care. 2018 Jan.35(1):144-150. Pubmedid: 28299946.
    • Denson A, Burke N, Wapinsky G, Bertels B, Juan TH, Lee J, Springett GM, Strosberg JR, Kim RD, Sullivan DM, Mahipal A. Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol. 2018 Feb.41(2):133-139. Pubmedid: 26523441. Pmcid: PMC4980275.
    • Kim RD, Alberts SR, Peña C, Genvresse I, Ajavon-Hartmann A, Xia C, Kelly A, Grilley-Olson JE. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. Brit J Cancer. 2018 Feb.118(4):462-470. Pubmedid: 29348486. Pmcid: PMC5830590.
    • Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, Cohn AL, Bekaii-Saab TS, Leonard G, Ryan T, Olowokure OO, Fernando NH, McCaffrey J, El-Rayes BF, Horgan AM, Sherrill GB, Yacoub GH, O'Neil BH. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Cancer. 2018 Aug.124(15):3118-3126. Pubmedid: 29905927.
    • Puri S, Hyland KA, Weiss KC, Bell GC, Gray JE, Kim R, Lin HY, Hoogland AI, Gonzalez BD, Nelson AM, Kinney AY, Fischer SM, Li D, Jacobsen PB, McLeod HL, Jim HSL. Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer. 2018 Aug.26(8):2911-2918. Pubmedid: 29546524. Pmcid: PMC6200138.
    • Gangi A, Shah J, Hatfield N, Smith J, Sweeney J, Choi J, El-Haddad G, Biebel B, Parikh N, Arslan B, Hoffe SE, Frakes JM, Springett GM, Anaya DA, Malafa M, Chen DT, Chen Y, Kim RD, Shridhar R, Kis B. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study. J Vasc Interv Radiol. 2018 Aug.29(8):1101-1108. Pubmedid: 30042074. Pmcid: PMC7771272.
    • Ashraf N, Kim R. Treatment of Gastric and Gastroesophageal Cancers-Do We Really Need Anthracyclines?. JAMA Oncol. 2017 Sep.3(9):1172-1173. Pubmedid: 27584978.
    • Sandoval-Sus JD, Mogollon-Duffo F, Patel A, Visweshwar N, Laber DA, Kim R, Jaglal MV. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. J Immunother Cancer. 2017 Jun.5:49. Pubmedid: 28642818. Pmcid: PMC5477132.
    • Kim R, Chiorean EG, Amin M, Rocha-Lima CMS, Gandhi J, Harris WP, Song T, Portnoy D. Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment. Brit J Cancer. 2017 Jul.117(2):189-194. Pubmedid: 28632730. Pmcid: PMC5520510.
    • Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017 Apr.8(2):256-265. Pubmedid: 28480065. Pmcid: PMC5401857.
    • Kim DW, Byer J, Kothari N, Mahipal A, Chang YD, Kim RD. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Oncology-Basel. 2017 Apr.92(4):190-196. Pubmedid: 28152526.
    • Kothari N, Teer JK, Abbott AM, Srikumar T, Zhang Y, Yoder SJ, Brohl AS, Kim RD, Reed DR, Shibata D. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers. Cancer. 2016 Sep.122(18):2828-2835. Pubmedid: 27244218. Pmcid: PMC5014625.
    • Bustamante L, Frakes J, Hoffe S, Kim R. Investigational drugs for treating anal cancer and future perspectives. Expert Opin Inv Drug. 2016 Sep.25(1):51-62. Pubmedid: 26560877.
    • Mohammadi H, Abuodeh YA, Jin W, Frakes JM, Friedman M, Biebel B, Choi J, El-Haddad GE, Kis B, Sweeney J, Kim R, Pimiento JM, Malafa MP, Anaya D, Hoffe SE. Using the ALBI Grade as a Prognostic Marker for Radioembolization of Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E194-E195.
    • Pearson AL, Jin W, Mellon EA, Frakes JM, Strom T, Springett GM, Kim R, Mahipal A, Hodul PJ, Pimiento JM, Shridhar R, Malafa MP, Hoffe SE. Post-Stereotactic Body Radiation Therapy (SBRT) Neutrophil-to-Lymphocyte Ratio (NLR) in Patients With Borderline Resectable Pancreatic Cancer (BRPC) May Be a Prognostic Biomarker. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E153. Pubmedid: 27673917.
    • Jin W, Mellon EA, Hoffe SE, Frakes JM, Springett GM, Centeno BA, Kim R, Mahipal A, Pimiento JM, Malafa MP, Latifi K. Does Metabolic Tumor Volume Predict Tumor Regression Grade After Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer?. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E195. Pubmedid: 27674030.
    • Pimiento JM, Davis-Yadley AH, Kim RD, Chen DT, Eikman EA, Berman CG, Malafa MP. Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer. Clin Nucl Med. 2016 Mar.41(3):177-181. Pubmedid: 26673243. Pmcid: PMC4740191.
    • Kim R, Prithviraj GK, Shridhar R, Hoffe SE, Jiang K, Zhao X, Chen DT, Almhanna K, Strosberg J, Campos T, Shibata D. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. Radiother Oncol. 2016 Feb.118(2):382-386. Pubmedid: 26861740. Pmcid: PMC7771531.
    • Abuodeh Y, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafa M, Frakes JM, Hoffe SE, El-Haddad G. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. World J Gastroenterol. 2016 Dec.22(47):10406-10414. Pubmedid: 28058021. Pmcid: PMC5175253.
    • Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 Dec.34(34):4142-4150. Pubmedid: 26926685. Pmcid: PMC5562433.
    • Doepker MP, Thompson ZJ, Centeno BA, Kim RD, Wong J, Hodul PJ. Clinicopathologic and survival analysis of resected ampullary adenocarcinoma. J Surg Oncol. 2016 Aug.114(2):170-175. Pubmedid: 27158031. Pmcid: PMC7771532.
    • Suleiman Y, Mahipal A, Shibata D, Siegel EM, Jump H, Fulp WJ, Springett GM, Kim R. Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2015 Sep.76(3):481-487. Pubmedid: 26126727.
    • Abbott AM, Kim R, Hoffe SE, Arslan B, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Meredith KL, Almhanna K, Strosberg J, Shibata D, Fulp WJ, Shridhar R. Outcomes of Therasphere Radioembolization for Colorectal Metastases. Clin Colorectal Cancer. 2015 Sep.14(3):146-153. Pubmedid: 25795047.
    • Kim R, Yamauchi T, Husain K, Sebti S, Malafa M. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells. Anticancer Res. 2015 Sep.35(9):4599-4604. Pubmedid: 26254348.
    • Mahipal A, Choi M, Kim R. Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?. J Natl Compr Canc Ne. 2015 Oct.13(10):1281-1291. Pubmedid: 26483065.
    • Mahipal A, Shibata D, Siegel E, Springett G, Almhanna K, Fulp W, Williams-Elson I, Kim R. Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies. Invest New Drugs. 2015 Oct.33(5):1093-1099. Pubmedid: 26275531. Pmcid: PMC7882394.
    • Mahipal A, Frakes J, Hoffe S, Kim R. Management of borderline resectable pancreatic cancer. World J Gastrointest Oncol. 2015 Oct.7(10):241-249. Pubmedid: 26483878. Pmcid: PMC4606178.
    • Kim R, Prithviraj G, Kothari N, Springett G, Malafa M, Hodul P, Kim J, Yue B, Morse B, Mahipal A. PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer. Clin Nucl Med. 2015 Nov.40(11):e501-e505. Pubmedid: 26053713. Pmcid: PMC4813735.
    • Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M, Yeatman TJ. Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. PLoS One. 2015 May.10(5):e0126670. Pubmedid: 25974029. Pmcid: PMC4431733.
    • Ashraf N, Hoffe S, Kim R. Locally advanced gastroesophageal junction tumor: a treatment dilemma. Oncologist. 2015 Feb.20(2):134-142. Pubmedid: 25561508. Pmcid: PMC4319638.
    • Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin S, Kim RD, Casey M, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, Kudo M. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol. 2015 Dec.26(12):2457-2463. Pubmedid: 26386123.
    • Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong HL, Farragher I, Jones I, Day FL, Li S, Sakthinandeswaren A, Palmieri M, Lipton L, Schell M, Teer JK, Shibata D, Yeatman T, Sieber OM, Gibbs P, Tran B. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol. 2015 Apr.54(4):487-492. Pubmedid: 25549537. Pmcid: PMC4743650.
    • Sanoff HK, Kim R, Ivanova A, Alistar A, McRee AJ, O'Neil BH. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Invest New Drugs. 2015 Apr.33(2):505-509. Pubmedid: 25613083. Pmcid: PMC4487887.
    • Kothari N, Schell MJ, Teer JK, Yeatman T, Shibata D, Kim R. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. J Clin Pathol. 2014 Sep.67(9):764-767. Pubmedid: 25004944. Pmcid: PMC4743643.
    • Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology-Basel. 2014 Sep.87(2):125-132. Pubmedid: 25012155.
    • Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist. 2014 Sep.18(9):1013-1021. Pubmedid: 23966224. Pmcid: PMC3780633.
    • Ashraf N, Kothari N, Kim R. Predictive biomarkers for anti-epidermal growth factor receptor therapy: beyond KRAS testing. J Natl Compr Canc Ne. 2014 Oct.12(10):1433-1442. Pubmedid: 25313182.
    • Fujiki M, Aucejo F, Choi M, Kim R. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand?. World J Gastroenterol. 2014 May.20(18):5308-5319. Pubmedid: 24833861. Pmcid: PMC4017046.
    • Waghray A, Balci B, El-Gazzaz G, Kim R, Pelley R, Menon KN, Estfan B, Romero-Marrero C, Aucejo F. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant. 2014 Mar.27(4):555-561. Pubmedid: 23758296.
    • Ashraf N, Hoffe S, Kim R. French FNCLCC/FFCD 9703 study. Oncologist. 2014 Apr.19(4):431. Pubmedid: 24729607. Pmcid: PMC3983828.
    • Kim R, Tan A, Choi M, El-Rayes BF. Geographic differences in approach to advanced gastric cancer: Is there a standard approach?. Crit Rev Oncol Hematol. 2013 Nov.88(2):416-426. Pubmedid: 23764501.
    • Kothari N, Saif MW, Kim R. First-line treatment for advanced pancreatic cancer. JOP. 2013 Mar.14(2):129-132. Pubmedid: 23474553.
    • Kim R, Mahipal A, Choi M, Saif MW. Biomarkers for pancreatic cancer: is it ready for primetime?. JOP. 2013 Jul.14(4):309-311. Pubmedid: 23846914.
    • Xie H, Jiang W, Jiang J, Wang Y, Kim R, Liu X, Liu X. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer. 2013 Jan.119(1):173-181. Pubmedid: 22736490.
    • Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2013 Aug.36(4):319-324. Pubmedid: 22547010.
    • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May.48(7):997-1003. Pubmedid: 22445247. Pmcid: PMC4522922.
    • Kim R, Byer J, Saif MW. BRCA and pancreatic cancer: selection of chemotherapy. JOP. 2012 Mar.13(2):180-181. Pubmedid: 22406596.
    • Choi M, Kim R, Saif MW. What options are available for refractory pancreatic cancer?. JOP. 2012 Mar.13(2):163-165. Pubmedid: 22406591.
    • Kim R, Kubal T. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer. Clin Colorectal Cancer. 2012 Jun.11(2):85-87. Pubmedid: 22169039.
    • Choi M, Razzaque S, Kim R. Systemic therapy of advanced pancreatic cancer: has the landscape changed?. Clin Adv Hematol Oncol. 2012 Jul.10(7):442-451. Pubmedid: 22895284.
    • Fujiki M, Aucejo F, Kim R. General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?. Liver Int. 2011 Sep.31(8):1081-1089. Pubmedid: 22008644.
    • Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. Predictors of clinical outcomes of resected ampullary adenocarcinoma: a single-institution experience. Eur J Surg Oncol. 2011 Sep.37(9):791-797. Pubmedid: 21741199.
    • Kim R, Byrne MT, Tan A, Aucejo F. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. Oncology (Williston Park). 2011 Mar.25(3):283-91, 295. Pubmedid: 21548473.
    • Kim R, Aucejo F. Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. J Gastrointest Cancer. 2011 Mar.42(1):50-53. Pubmedid: 20714941.
    • Liu X, Jiang W, Aucejo F, Kim R, Miller C, Byrne M, Lopez R, Yerian L. Insulin-like growth factor I receptor β expression in hepatocellular carcinoma. Hum Pathol. 2011 Jun.42(6):882-891. Pubmedid: 21292299.
    • Kim R, Chabot J, Saif MW. Adjuvant treatment for ampullary cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP. 2011 Jul.12(4):362-363. Pubmedid: 21737897.
    • Kim R, Tan A, Lai KK, Jiang J, Wang Y, Rybicki LA, Liu X. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer. 2011 Jul.117(14):3126-3134. Pubmedid: 21264835.
    • Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?. Lancet Oncol. 2011 Jan.12(1):8-9. Pubmedid: 21050812.
    • Kim R, El-Gazzaz G, Tan A, Elson P, Byrne M, Chang YD, Aucejo F. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology-Basel. 2011 Jan.79(1-2):62-66. Pubmedid: 21071991.
    • Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN, Kim R, Menon KV. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011 Dec.22(12):1697-1705. Pubmedid: 21983055.
    • Kim R, Menon N, Aucejo F. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. Med Oncol. 2011 Dec.28(4):1044-1047. Pubmedid: 20635167.
    • Phillips B, Kalady M, Kim R. BRAF testing in advanced colorectal cancer: is it ready for prime time?. Clin Adv Hematol Oncol. 2010 Jun.8(6):437-444. Pubmedid: 20733556.
    • Tan A, Aucejo F, Kim R. Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma?. Oncology. 2010 Jun.78(3-4):161-171. Pubmedid: 20530972.
    • Kim R, Tsao R, Tan A, Byrne M, Almhanna K, Lazaryan A, Elson P, Pelley RJ. A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators. J Gastrointest Surg. 2010 Jul.14(7):1159-1169. Pubmedid: 20446118.
    • Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncol. 2009 Sep.10(9):903-912. Pubmedid: 19717092.
    • Anderson C, Kim R. Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev. 2009 Jun.35(4):322-327. Pubmedid: 19147294.
    • Aucejo F, Kim R, Zein N, Quintini C, Uso TD, Lopez R, Eghtesad B, Fung J, Miller C, Yerian L. Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria. Liver Transpl. 2009 Feb.15(2):169-176. Pubmedid: 19177438.
    • Kim R. Cetuximab and panitumumab: are they interchangeable?. Lancet Oncol. 2009 Dec.10(12):1140-1141. Pubmedid: 19875336.
    • Kim R, Tan A, Estfan B, Aucejo F. Adjuvant treatment after orthotopic liver transplantation: is it really necessary?. Oncology (Williston Park). 2009 Dec.23(14):1276-1281. Pubmedid: 20120841.
    • Almhanna K, Kim R. Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?. Oncology (Williston Park). 2008 Sep.22(10):1176-1183. Pubmedid: 18935928.
    • Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis. 2008 Feb.23(2):139-145. Pubmedid: 17909820.
    • Saif MW, Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother. 2007 Nov.8(16):2719-2727. Pubmedid: 17956194.
    • Kim R, Saif MW. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?. JOP. 2007 May.8(3):279-288. Pubmedid: 17495356.
    • Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf. 2007 Mar.6(2):175-182. Pubmedid: 17367263.
    • Almhanna K, Kalmadi S, Pelley R, Kim R. Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?. Oncology (Williston Park). 2007 Aug.21(9):1116-1122. Pubmedid: 17910314.
    • Eatrides J, Wang E, Kothari N, Kim R. Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma. Cancer Control. 24(3):1073274817729243. Pubmedid: 28975834. Pmcid: PMC5937243.
  • Grants

    Title: Feasibility assessment for real-world evidence analysis of hepatocellular carcinoma (HCC) patients from Moffitt treated with Tecentriq + Avastin regimen
    Sponsor: Genentech, Inc.
    PI: Kim, R.
  • Patient Comments

    Overall Satisfaction

    4.8

    120 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey

     

    Comments

    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor